Table 2.
Baseline characteristics for erdafitinib-treated patients
| Characteristic | All erdafitinib-treated patients (N = 32) | Erdafitinib-treated patients with cfDNA (n = 27) |
|---|---|---|
| Median age, years (range) | 72 (57–86) | 72 (57–86) |
| Female, n (%) | 9 (28) | 7 (26) |
| Race, n (%) | ||
| African American | 2 (6) | 2 (7) |
| Caucasian | 29 (91) | 24 (89) |
| Other/Unknown | 1 (3) | 1 (4) |
| ECOG PS, n (%) | ||
| 0 | 6 (19) | 5 (19) |
| 1 | 20 (63) | 17 (63) |
| 2 | 5 (16) | 5 (19) |
| Unknown | 1 (3) | 0 (0) |
| Tumor histology, n (%) | ||
| Urothelial cancer, NOS | 25 (78) | 24 (89) |
| Urothelial cancer with squamous differentiation | 5 (16) | 1 (4) |
| Urothelial cancer with micropapillary features | 1 (3) | 1 (4) |
| Poorly differentiated urothelial carcinoma | 1 (3) | 1 (4) |
| Primary site of disease, n (%) | ||
| Bladder/urethral | 20 (63) | 16 (59) |
| Upper tract | 6 (19) | 5 (19) |
| Bladder/urethral & upper tract | 6 (19) | 6 (22) |
| Visceral metastases, n (%) | 29 (91) | 26 (96) |
| Liver metastases, n (%) | 15 (47) | 13 (48) |
| Prior anti-PD-1/L1, n (%) | 24 (89) | 21 (78) |
| Prior ADC, n (%) | 12 (44) | 11 (41) |
| Prior lines of therapy, n (%) | ||
| 0 | 0 (0) | 0 (0) |
| 1 | 8 (25) | 6 (22) |
| 2 | 13 (41) | 11 (41) |
| 3 | 4 (13) | 4 (15) |
| 3+ | 7 (22) | 6 (22) |
Abbreviations: ADC, antibody-drug conjugate; cfDNA, cell-free DNA; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NOS, not otherwise specified